Clinical trial
FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously…
NCT00254410 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00254410 |
|---|---|
| Title | FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years |
| Official title | Phase 2 Study of the Activity and Safety of Fludarabine, Cyclophosphamide, and Mitoxantrone Plus Rituximab (FCM-R) With Pegfilgrastim (Neulasta) as Frontline Therapy for Patients < 70 Years With Chronic Lymphocytic Leukemia |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | OSI Pharmaceuticals Industry Genentech, Inc. |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab, Filgrastim |
| Enrollment | 30 |
| Start date | Mar 14, 2005 |
| Primary completion | Sep 14, 2017 |
| Completion | Sep 14, 2017 |
| First posted | Nov 16, 2005 |
| Last update posted | May 1, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: